Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cumberland Pharmaceuticals Inc
NASDAQ:CPIX
|
US |
|
P
|
Piaggio & C SpA
XMUN:P1I
|
IT |
|
Metalpha Technology Holding Ltd
NASDAQ:MATH
|
HK |
|
Bidvest Group Ltd
F:NQL
|
ZA |
|
H
|
Halliburton Co
DUS:HAL
|
US |
|
Darma Henwa Tbk PT
F:0DH
|
ID |
|
B
|
BGrimm Power PCL
SET:BGRIM
|
TH |
|
3
|
3M Co
XHAM:MMM
|
US |
|
A
|
Apple Inc
XHAM:APC
|
US |
|
DeFi Technologies Inc
F:R9B
|
CA |
|
B
|
Bank of America Corp
XHAM:NCB
|
US |
|
I
|
Itama Ranoraya PT
IDX:IRRA
|
ID |
|
TraWell Co SpA
OTC:TRWAF
|
IT |
|
G
|
General Engineering PCL
SET:GEL
|
TH |
|
EMCOR Group Inc
NYSE:EME
|
US |
|
YPF SA
NYSE:YPF
|
AR |
|
C
|
Capex SA
BCBA:CAPX
|
AR |
|
Rakuten Group Inc
F:RAK
|
JP |
Earnings Calls
Last Earnings Call
Strategic reset: Cumberland completed the Apotex transaction on July 1, selling its U.S. commercial brands and shifting the company into a more development-focused biopharma model.
Cash strength: Management said the deal brought in $100 million at closing, with another $11 million expected, and that the company plans to use the capital to fund development for more than 5 years.
Quarterly loss: Second-quarter operating loss was $3.1 million, and net loss was $4.1 million after discontinued operations.
Pipeline focus: The company highlighted ifetroban programs in DMD, systemic sclerosis, IPF, and oncology, with several clinical readouts expected in 2026.
Capital return: The board declared a special dividend of $1.50 per share, totaling $22 million.
Next steps: Management said it will keep working with the FDA on the DMD program, report systemic sclerosis top-line data this year, and report interim efficacy data for IPF this year.